Literature DB >> 29633526

MicroRNAs as possible biomarkers for hepatocellular carcinoma.

Asahiro Morishita1, Tsutomu Masaki1.   

Abstract

Entities:  

Year:  2018        PMID： 29633526     DOI： 10.1111/hepr.13078

Source DB:  PubMed          Journal:  Hepatol Res        ISSN： 1386-6346            Impact factor:   4.288


× No keyword cloud information.
  5 in total

1.  Dynamics of Circulating miR-122 Predict Liver Cancer and Mortality in Japanese Patients with Histopathologically Confirmed NAFLD and Severe Fibrosis Stage.

Authors:  Norio Akuta; Yusuke Kawamura; Fumitaka Suzuki; Satoshi Saitoh; Yasuji Arase; Nozomu Muraishi; Shunichiro Fujiyama; Hitomi Sezaki; Tetsuya Hosaka; Masahiro Kobayashi; Mariko Kobayashi; Yoshiyuki Suzuki; Kenji Ikeda; Hiromitsu Kumada
Journal:  Oncology       Date:  2021-11-17       Impact factor: 2.935

2.  miR-145-5p Acts as a Novel Tumor Suppressor in Hepatocellular Carcinoma Through Targeting RAB18.

Authors:  Baoying Wang; Wenjing Dong; Xiaojie Li
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

Review 3.  Molecular and Functional Roles of MicroRNAs in the Progression of Hepatocellular Carcinoma-A Review.

Authors:  Kyoko Oura; Asahiro Morishita; Tsutomu Masaki
Journal:  Int J Mol Sci       Date:  2020-11-07       Impact factor: 5.923

4.  MiRNA Polymorphisms and Hepatocellular Carcinoma Susceptibility: A Systematic Review and Network Meta-Analysis.

Authors:  Qimeng Zhang; Xueying Xu; Mingcheng Wu; Tiantian Qin; Shaoning Wu; Hongbo Liu
Journal:  Front Oncol       Date:  2021-01-19       Impact factor: 6.244

5.  Circulating MicroRNA-122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD.

Authors:  Norio Akuta; Yusuke Kawamura; Yasuji Arase; Satoshi Saitoh; Shunichiro Fujiyama; Hitomi Sezaki; Tetsuya Hosaka; Masahiro Kobayashi; Mariko Kobayashi; Yoshiyuki Suzuki; Fumitaka Suzuki; Kenji Ikeda; Hiromitsu Kumada
Journal:  Hepatol Commun       Date:  2019-11-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.